References
- Ampyra® [dalfampridine] extended release tablets prescribing information. Ardsley, NY: Acorda Therapeutics, Inc., January 2013
- Goodman AD, Brown TR, Krupp L, et al. Sustained release of oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial. Lancet 2009;373:732-8
- Goodman AD, Brown TR, Edwards KR, et al. A phase 3 trial of extended release oral dalfampridine in mulitple sclerosis. Ann Neurol 2010;68:494-502
- Dunn J, Blight A. Dalfampridine: a brief review of its mechanism of action and efficacy as a treatment to improve walking in patients with multiple sclerosis. Curr Med Res Opin 2011;27:1415-23
- Lundh H, Thesleff S. The mode of action of 4-aminopyridine and guanidine on transmitter release from motor nerve terminals. Eur J Pharmacol 1977;42:411-2
- Kirsch GE, Drewe JA. Gating-dependent mechanism of 4-aminopyridine block in two related potassium channels. J Gen Physiol 1993;102:797-816
- Mahmood I, Green MD. Drug interaction studies of therapeutic proteins or monoclonal antibodies. J Clin Pharmacol 2007;47:1540-54
- Schapiro R, Brown T, Goodman A; On Behalf of the MS-F202 M-F, and MS-F204 Study Groups. Evaluation of orally administered prolonged-release fampridine tablets for walking improvement in patients with multiple sclerosis treated with disease-modifying therapies. [abstract]. Mult Scler 2010;16(Suppl):S174
- Vollmer T, Henney HR. Pharmacokinetics and tolerability of single escalating doses of fampridine sustained-release tablets in patients with multiple sclerosis: a phase I-II, open-label trial. Clin Ther 2009;31:2206-14
- Vollmer T, Blight AR, Henney HR. Steady-state pharmacokinetics and tolerability of orally administered fampridine sustained release 10-mg tablets in patients with multiple sclerosis: a 2-week, open-label, follow-up study. Clin Ther 2009;31:2215-23
- Blight AR, Henney HR. Pharmacokinetics of 14C-radioactivity after oral intake of a single dose of 14C-labeled fampridine (4-aminopyridine) in healthy volunteers. Clin Ther 2009;31:328-35
- Smith W, Swan S, Marbury T, et al. Single-dose pharmacokinetics of sustained-release fampridine (Fampridine-SR) in healthy volunteers and adults with renal impairment. J Clin Pharmacol 2010;50:151-9
- Henney HR 3rd, Blight A, Faust B. Effect of food on the single-dose pharmacokinetics and tolerability of dalfampridine extended-release tablets in healthy volunteers. Am J Health Syst Pharm 2011;68:2148-54
- United States Food and Drug Administration. Guidance for Industry. Drug Interaction Studies — Study design, data analysis, and implications for dosing and labeling. Draft Guidance. US Department of Health and Human Services. Rockville, MD: Center for Drug Evaluation and Research; September 2006
- Ogilvie BW, Zhang D, Li W, et al. Glucuronidation converts gemfibrozil to a potent, metabolism-dependent inhibitor of CYP2C8: implications for drug-drug interactions. Drug Metab Dispos 2006;34:191-7
- Ogilvie BW, Usuki E, Yerino P, et al. In vitro approaches for studying the inhibition of drug-metabolizing enzymes and identifying the drug-metabolizing enzymes responsible for the metabolism of drugs (reaction phenotyping) with emphasis on cytochrome P450. In: Rodrigues AD, ed. Drug-drug interactions drugs and the pharmaceutical sciences. 2nd edn. New York: Informa Healthcare, 2008. p 231-358
- Quistorff B, Dich J, Grunnet N. Preparation of isolated rat liver hepatocytes. In: Pollard JW, Walker JM, eds. Methods in molecular biology. Volume 5. Animal cell culture. Clifton, NJ: Humana Press. 1989. p 151-60
- Madan A, Graham RA, Carroll KM, et al. Effects of prototypical microsomal enzyme inducers on cytochrome P450 expression in cultured human hepatocytes. Drug Metab Dispos 2003;31:421-31
- Sonderfan AJ, Parkinson A. Inhibition of steroid 5 alpha-reductase and its effects on testosterone hydroxylation by rat liver microsomal cytochrome P-450. Arch Biochem Biophys 1988;265:208-18
- Evenhuis J, Agoston S, Salt PJ, et al. Pharmacokinetics of 4-aminopyridine in human volunteers. A preliminary study using a new GLC method for its estimation. Br J Anaesth 1981;53:567-70
- Uges DR, Sohn YJ, Greijdanus B, et al. 4-Aminopyridine kinetics. Clin Pharmacol Ther 1982;31:587-93
- Caggiano A, Blight A. Identification of metabolites of dalfampridine (4-Aminopyridine) in human subjects and reaction phenotyping of relevant cytochrome P450 pathways. J Drug Assessment 2013